Format

Send to

Choose Destination
See comment in PubMed Commons below
Case Rep Oncol. 2012 Sep;5(3):506-10. doi: 10.1159/000343043. Epub 2012 Sep 28.

Hepatic artery chemoembolization for hepatocellular carcinoma recurrence confined to the transplanted liver.

Author information

1
Department of Nutrition and Experimental Biology, IRCCS Saverio de Bellis Medical Research Institute, Castellana Grotte, Italy.

Abstract

BACKGROUND:

Careful hepatocellular carcinoma (HCC) case selection permits orthotopic liver transplantation with the expectation of around 70% plus 5-year survival. However, many patients have tumor recurrences and there is little literature guidance in the management of these patients.

AIMS:

A retrospective examination of patients transplanted with HCC who subsequently developed liver recurrence.

METHODS:

A case cohort series of patients was prospectively followed who had liver-only multifocal tumor recurrence of HCC after liver transplant and were then treated with chemoembolization.

RESULTS:

All 6 patients had recurrent HCC. 2 had no response, 1 had stable disease, 2 had partial response (PR) and 1 had complete disappearance (CR) of disease. Their survival (in months) was: 13 (no response), 18 (no response), 12 (stable disease), 19 (PR), 30 (PR) and 50 (CR). There were no liver toxicities.

CONCLUSIONS:

Chemoembolization for tumor recurrence in the transplanted liver is as safe as or safer than in the pre-transplant liver, due to the absence of cirrhosis. In this series, there were 3 of 6 responses with some long survivors.

KEYWORDS:

Chemoembolization; Hepatocellular carcinoma; Liver transplant; Tumor responses

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for S. Karger AG, Basel, Switzerland Icon for PubMed Central
    Loading ...
    Support Center